Martin W. Beasley, Ph.D., R.Ph.
`
`Cary, NC
`
` martinbeasleypharm@gmail.com
`
` 919-605-5032
`
` SUMMARY
`
`Seasoned pharmaceutical scientist with broad experience in NDA/sNDA/ANDA product development,
`contract pharma development, and virtual product development. Skilled in all pharmaceutical dosage
`forms (oral, parenteral, topical) for small and large molecules, technical transfer, clinical and scale-up
`manufacturing, due diligence, patent support, FDA/regulatory and technical marketing/sales support.
`Expertise includes:
`• Dosage Form Design/Formulation/Evaluation from Clinical through Scale-Up Manufacturing
`• Technical Transfer of clinical dosage forms to pharmaceutical sites for product manufacturing
`Patent Evaluations and Applications
`•
`• Due Diligence for acquisition of products, technologies and/or companies
`• Chemistry, Manufacturing & Controls regulatory documentation and on-site meetings at FDA
`Strategic sourcing and budgeting of pharmaceutical services from internal and external partners
`•
`Project Management/Technical Marketing/Consultative Sales Support
`•
`Pharmacy Practice in teaching university hospital and military outpatient pharmacy
`•
`
` PHARMACEUTICAL CURRICULUM VITAE
`
`Pharmaceutical Development Consultant – Cary, NC Martin Beasley Jan 2012 - present
`Provide expert pharmaceutical and patent opinion to clients investigating therapeutic product
`development for pain, Parkinson’s disease, CNS stimulation, and anti-microbial garments. Serve
`as Scientific Advisory Board member for NextGen Development Group LLC. Earned APHA
`Certificates of Achievement in Pharmacy Based Immunization Delivery, April 2013; Pharmacist
`and Patient-Centered Diabetes Care, June 2013; American Heart Association Certified BLS
`(CPR and AED) for Healthcare Providers (July 2015; July 2013).
`
`Pfizer Pharmaceutical Development – Cary, NC Mar 2011 - Nov 2011
`King Pharmaceuticals Research & Development, Inc. – Cary, NC Dec 2003 - Mar 2011
`Senior Director, Pharmaceutical Development
`Designed, planned and budgeted formulation development protocols; Wrote request for proposals;
`Supervised director of formulations, director of pharmaceutical development, and principal and senior
`scientists; Coordinated and evaluated dosage form development of adenosine-receptor NCEs, licensed
`drug delivery platforms (narcotic analgesics, transdermal patch) and managed product life cycle (patented
`delivery platforms) for King Pharmaceuticals’ branded products. Coordinated and directed virtual CMC
`activities with contract development partners. Served as a King due diligence team member, and
`evaluated more than 200 opportunities with potential partners’ intellectual property, including research
`and/or brand products for licensing/purchase/co-development. Transferred technology to Pfizer in 2011.
`• Completed knowledge transfer of Remoxy, Bupivacaine Transdermal Therapeutic System,
`and Levoxyl tablets to Pfizer (three different project teams and sites) 3/2011 – 11/2011.
`• Led Sub-CMC Team for Remoxy extended release capsules, following Complete Response
`Letter to DURECT, 12/2008. Under extreme one-year deadline, led multi-discipline CMC
`team through challenging dosage form attributes with external partners (in-vitro abuse
`deterrent tests; comparison vs. marketed reference product), manufacture of NDA
`resubmission batches (4Q2009), and writing Modules 2 & 3 for the eCTD.
`Result: NDA resubmission accomplished 12/2010.
`
`Complex Ex. 1011
`
`1
`
`

`

`
`• Served as a key CMC due diligence team member for 12/2008 ALPharma acquisition,
`targeting Embeda (extended release morphine sulfate and naltrexone hydrochloride), Flector
`Patch, and AL02 (extended release oxycodone hydrochloride and naltrexone hydrochloride).
`Coached director of formulations in the tech transfer of AL02 extended release capsules
`while simultaneously closing and transferring physical assets from ALPharma and
`negotiating multi-$million contract with external partner for technical transfer/scale-up in late
`2009. Result: NDA submission batches successfully manufactured/delivered on-time in
`4Q2010. FDA accepted AL02 NDA submission on 13 February 2015.
`• Led SubCMC Team for Bupivacaine Transdermal Therapeutic System, licensed from
`DURECT (via ALPharma purchase). Led cross-functional team, including external partner.
`Result: Coordinated manufacture of Phase 2A batches for chronic lower back pain trial from
`late 2009 through 4/2010. Identified, selected, and negotiated tech transfer/scale-up with
`chosen commercial partners for Phase 3 submission batches in 2010.
`• Coached principal scientist in developing Binodenosan for injection (A2A agonist
`pharmacological stress agent for cardiac imaging).
`Result: CorVue NDA submission batches completed and Module 3 eCTD quality control
`executed. NDA submitted 12/2008 (FDA accepted CMC modules).
`• Directed/coached senior scientist in developing Phase I hard gel/liquid fill cap (CNS)
`Result: IND filed 3Q2008. Clinical trial cancelled based on business case review.
`• Coached King-St.Petersburg (FL) scientist through Levoxyl tablets (levothyroxine sodium)
`reformulation and tech transfer/scale-up at Bristol site, resulting in superior stability.
`Result: NDA supplement filed in 3Q2008 and product approved 1Q2011.
`• Served as Key CMC due diligence team member for Avinza (morphine sulfate modified
`release beads) acquisition from Ligand, 02/2007. Collaborated PLCM activity with partner
`Elan. Result: 2 new SKU’s (intermediate 45mg and 75mg strengths) approved 12/2008.
`• Served as Key CMC due diligence team member for securing Acura tablets (Aversion
`platform) license, 11/2006. Coached director of formulations in Phase 3 activities/follow-on
`products. Result: Aversion licensed 11/2005; renamed Oxecta tablets. FDA approved 6/2011.
`• Key CMC due diligence team member for securing Remoxy (oral abuse deterrent dosage
`form) license with Pain Therapeutics, Inc., 11/2005.
`Result: Remoxy licensed 11/2005.
`Mentored principal scientist in successfully executing collaborative Phase 3 activities and
`initiated plans for Remoxy follow-on products.
`• Served as key CMC team member for Metaxolone PLCM activities with two external
`development partners, 11/2005 through mid-2009.
`• Mentored director of formulations in successful completion of NDA submission batches for
`ramipril/hydrochorothiazide tablets (three sku’s) and IND CMC submission (3/2006). NDA
`submission filed 4Q07 (later withdrawn).
`• Mentored senior scientist and director of formulations in successful formulation of IND
`Ramipril tablet product with superior stability profile. IND filed 5/2004 and tech
`transfer/CTM manufacture completed in 3Q2006. Project terminated late 3Q 2006.
`• Mentored senior scientist and director of formulations in successful formulation of NDA
`Ramipril/chlorthalidone combination tablet product. NDA filed 6/2004.
`• Coached principal scientist in writing FDA briefing document that successfully argued for
`manufacturing Phase 2 MRE0094 gel product under non-aseptic conditions due to inherent,
`self-preserving/chemically sterile properties. Phase 2 batches manufactured (3/2006) and
`dosed in clinical trial. Technical transfer of analytical methods completed, but commercial
`scale-up ended 01/ 2008, due to non-achievement of primary clinical endpoint.
`
`2
`
`

`

`
`
`• Coached principal scientist in coordinating MRE0094 injectable formulation with Preclinical
`group and contract tox lab in preparation of two-year carcinogenicity study. Program
`cancelled after Phase 2 clinical trial completion.
`• Directed and coached senior scientist in developing new modified release dosage form for
`Cytomel Tablets (liothyronine sodium). Lead prototypes with various release profiles were
`identified in 3 different dog PK studies (07/2004; 3Q 2005). IND filed 3/2006 and 2 test
`articles dosed in POC study, 05/2006. PK data revealed a potential, unique dosing pathway.
`• Collaborated as a Key CMC scientist with T3 Therapeutics for investigating modified release
`liothyronine sodium beads. UK due diligence trip (Archimedes, 6/2005) defined IND
`suitability. Dosed test article in dog PK study #3 (8/2005), coordinated analytical verification
`activities (2005 – 2006), and advised partner for dosing beads in POC study. Coached and
`directed senior scientist for coordinating and reviewing analytical verification per FDA
`guidelines. Collaboration ended 11/2007.
`• Successfully negotiated contract with Pharmaceutical Profiles for the investigation of T-62 GI
`absorption via gamma scintigraphy (King’s first IMPD in the UK, 1Q2005). Phase 1 IMPD
`study completed in 2006. Coached/directed senior scientist in Phase 2 soft gel dosage
`formulation optimization. Optimized clinical trial material manufactured in 3/2007 and
`Phase 2A trial for chronic lower back pain completed in 1Q2009. Program cancelled in 2009
`due to liver toxicity.
`• Coached principal scientist in the feasibility development of oral dissolvable strips for Sonata
`(zaleplon). Project initiated 2004 but terminated 4/2006 due to market conditions.
`
`KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC Cary, NC April 2001-Dec 2003
`Director, Pharmaceutical Development
`Designed, planned and budgeted formulation development protocols; Wrote request for proposals;
`Coordinated and evaluated dosage form development of adenosine-receptor NCEs; Coordinated and
`directed virtual CMC activities with contract development partners; Coached formulation director and
`senior scientist development activities; Served as a King due diligence team member for evaluation
`and acquisition of technology.
`• Led successful formulation development and IND filing of King Pharmaceutical’s second
`Phase I NCE: T-62, an adenosine allosteric enhancer for neuropathic pain oral product. IND
`filed 8/2003.
`• Directed successful feasibility development of stable MRE0094 Injection for nine-month
`toxicity study support of MRE0094 gel Phase I (2002-2003).
`• Coached director of formulations in preclinical formulation support of A3 receptor antagonist
`identified as potential co-therapeutic oncology agent (4Q2003). Program cancelled in 2008
`due to business case.
`• Served as the key scientific contract negotiator for development of H2/calcium carbonate in a
`patented, orally disintegrating tablet platform with Eurand. In parallel, directed/coached
`senior scientist in successful development of stable, pleasant tasting prototype tablet with
`contract development partner. Project terminated in 6/2004.
`• Key scientific negotiator for contract closure with SkyePharma - King Pharmaceutical’s first
`drug delivery license - incorporating ramipril into SkyePharma’s patented, modified release
`GeoMatrix platform. License agreement signed 5/ 2003 but project terminated 8/2004.
`• Directed and coached senior scientist in successful taste masking of Tigan, an anti-emetic
`marketed as capsules and rectal suppositories. Stable, prototype oral solution identified in
`2003. Technology archived due to project termination in 4/2004.
`• Directed and coordinated transdermal patch prototype development for ramipril with drug
`delivery partner and transdermal consultant. Feasible prototype identified for in-vitro
`delivery of ramipril over 3.5 days (7/2002). Project terminated in 6/2004.
`
`3
`
`

`

`• Conceived idea for coating Levoxyl tablets to slow oral disintegration in direct response to
`consumer complaints (4Q2001). Directed/coached senior scientist in identifying feasible
`solvent coating process and feasible optimization of analytical methodology for prototype
`coated tablet. Project terminated in 6/2004.
`• Served as scientific advisor/ad hoc team member for PLCM dosage form development of
`Phase 2/Phase 3 Sonata MR and proposed Skelaxin MR with Elan. Project terminated in late
`2005.
`• Directed CMC for Phase I wound-healing MRE0094 topical gel formulation, an adenosine a1
`agonist. MRE0094 was King’s first NCE IND filing (4/2002).
`• Provided Business Development due diligence support for more than 200 different
`opportunities.
`
`
`
`
`
`
`
`
`AAI INTERNATIONAL - Wilmington, NC Sep 1991 – Apr 2001
`Technical Director, Global Product Development-Pharmaceutics (Apr 1999 – Apr 2001)
`
`Defined drug development and marketing needs for pharmaceutical clients, primarily in Eastern
`U.S., Michigan and Europe. Applied technical knowledge to match client needs, logistics, timeline,
`deliverables, and budget with AAI Pharmaceutics’ capabilities. Trained sales directors and
`pharmaceutical scientists in consultative sales technique. Acted as key contributor for $20MM in
`signed Product Development (Pharmaceutics) contracts for Year 2000.
`
`• Negotiated and coordinated marketing alliance with contract cGMP sterile
` manufacturer of Phase I/Phase 2a parenteral dosage forms (later acquired by AAI])
`• Utilized scientific expertise to help the group grow Pharmaceutics’ 1999 revenue by 14%
`• Continued the growth of multi-million dollar account for Phase III periodontal
` microcapsule dosage form--projected revenue growth 300% by 2002 and 650% by 2005
`
` (FDA approval 02/2001; marketed product is Arestin)
`
`• Marketed product development services with clients (on-site visits and at client site),
`
` International and national scientific meetings, company sponsored seminars, and telephone
`
`
`conferences
`
`
`
`
`
`Associate Director, Business Development/Process Technology, Manufacturing Services (Apr
`1998 – Apr 1999)
`Defined and marketed clinical trial manufacturing services and niche commercial manufacturing.
`Directed the Process Technology Group (Manager, Senior Packaging Engineer, Process Engineer,
`and Packaging Engineer) for scale-up manufacturing/packaging products:
` • Mentored the scale-up NDA submission batches for Phase 3 periodontal microcapsule
`(marketed as Arestin)
` • Mentored the scale-up of NDA submission batches for a Phase 3 male impotence tablet
` • Coached the scale-up and validation of highly potent Azathioprine 50mg tablet. Market
` launch of ANDA was 1999.
` • Monitored the process validation of doxycline capsule [Periostat] and SUPAC transfer of
`
`corticosteroid tablet that was completed/approved for 2 different clients, respectively.
` • Negotiated and closed contract for market labeling of an ANDA oncology parenteral
`
`product by packaging group, the first generic on U.S. market
` • Coached the upgrade and validation of the King packaging line with significantly increased
`
`bottle filling efficiency for the Azathioprine product and doxycyline product
` • Co-authored MSD section of five-year Pharmaceutics Business Plan
`
`
`
`4
`
`

`

`Director, Business Development, Clinical Services Division (Feb 1997 – Apr 1998)
`
` Identified, defined and marketed clinical trial manufacturing opportunities, helped grow the
` existing client base, and provided scientific dosage form development and scale-up
` manufacturing expertise to achieve division’s revenue target.
` • Scientific expertise was major factor for increasing the division's signed $ growth rate by
`
` 50% and signed contract rate by 14%, respectively, compared to 1996
` • Helped grow the Business Development group from 4 to 8 associates based on increased
`
` contract demand and signed contracts, due to travel with sales force.
` • Although officially transferred from operations into sales and marketing, maintained
` operations role as Project Leader for two ANDA projects until successful completion:
` Midazolam hydrochloride for Injection: ANDA filed 6/1997, on time-on budget, and
` approved for market 6/1999
` Azathioprine 50mg tablet: ANDA submitted11/1997 and approved for market 6/1999.
` • Continued consulting formulation development projects/tox ratings (Safety Advisory Team)
`
` Senior Manager, Formulations Development Laboratory (FDL) (Sept 1991 – Jan 1997)
`
` Coordinated and directed product development activities of 8 - 18 formulation scientists for
` IND/NDA, NADA and ANDA dosage forms. Prepared revenue/expense forecasts,
` Prepared capital budget requests, met with clients and outlined project plans to exceed their
` expectations, trained operations and sales personnel. Served on AAI Management Team, R & D
` Committee, Patent Committee, Controlled Substances Committee, and Safety Advisory Team.
` • Served as Project Leader for several IND teams: antiarrhythmic capsules; male impotence
` transurethral Pellets (MUSE); veterinary anti-inflammatory tablet; antiepileptic capsules
` • Served as Project Leader for several ANDA teams: antibiotic caps/tab/oral powder;
`
` anesthetic injection; controlled release anti-hypertension cap/tab; Azathioprine tablet
` • Managed INDs for Alzheimer tablet (Aricept10mg), anti-sepsis injection,
` antibiotic ophthalmic solution, anti-atherosclerosis injection, anti-multiple sclerosis
` injection, anti-sickle cell oral solution/injection, anti-viral cream, anti-inflammatory dental
` gel (Apthasol), and NDA supplement for anti-psychotic tablet (Nardil)
` • Managed ANDAs for two anti-ulcer injections, anti-inflammatory injection,
` Acyclovir anti-viral tablets, Estradiol tablets, hemorheologic tablet, Azathioprine tablet,
` anti-asthma oral solution/inhalation solution, and cystoscope dye injection. Managed ANDA
` injectable compatibility studies for antibiotic, antihypertensive, narcotic analgesic, and
` anesthetic drugs.
`
` APPLIED ANALYTICAL INDUSTRIES, INC. - Wilmington, NC Jun 1988 – Sept 1991
` Manager, Formulations Development (FDL) (May 1989 – Sept 1991)
`
` Coordinated and directed the product development activities of 19 formulation scientists.
` Prepared revenue/expense forecasts and prepared capital budget requests. Met with clients and
` outlined project plans to exceed their expectations, and trained operations/sales personnel.
` Prepared and coordinated development and stability reports for regulatory submission.
` • Reformulated anti-acne Stridex product – five new SKUs approved for the OTC market
` • Designed lyophilization cycles for peptide/protein parenteral dosage forms
` • Tech transferred German diuretic injection into cGMP facility (Demadex, NDA approved)
` • Appointed AAI’s 1st IND Project Leader for a multi-national Pharma client’s oral CNS
` dosage form program
` • Established and coordinated summer pharmacy internship program for industrial training
`
` of students from Campbell University and University of North Carolina-Chapel Hill
`
`5
`
`

`

`
` Senior Formulator, Formulations Development Company (FDL) Jun 1988 – May 1989
` Designed dosage forms, designed and monitored stability protocols, prepared and presented
` project status reports, supervised formulation scientists/cGMP operators in preparing
` lab scale/Phase I clinical trial materials. Met with clients and outlined project plans to exceed
` their expectations. Prepared development and stability reports.
` • Developed lyophilization cycle for a diagnostic immunoglobulin injection dosage form
` • Formulated and scaled-up Phase I topical dosage forms (antifungal/steroid product;
` anti-psoriasis gel)
` • Formulated pre-clinical Phase I topical dosage forms of a wound healing drug
`
` SCHERING RESEARCH, SCHERING-PLOUGH CORP. - Kenilworth, NJ July 1985 – June 1988
` Senior Scientist, Sterile Products Formulation Research
`
` Conducted formulation development of small molecules and recombinant proteins for product life
` cycle of nasal (Afrin), ophthalmic (Sulamyd), and parenteral dosage forms (Intron A)
` from preformulation to clinical manufacture. Designed and developed controlled release delivery
` systems for patent disclosure and PLCM. Prepared dosage form monographs, stability reports and
` development reports for IND/NDA submission.
`
` DEPARTMENT OF PHARMACEUTICS, UNIVERSITY OF MISSISSIPPI Sept 1979- Dec 1984
`
` Instructed 3rd/4th/5th year Pharmacy students in compounding/dispensing of medications and
` counseling patients about proper use of medications. Revised a Basic
` Pharmaceutics Laboratory course (10 labs) and taught to 3rd year pharmacy students.
`
` U.S. ARMY MEDICAL DEPARTMENT - Fort Sheridan, IL Jan 1976 – Aug 1979
` Chief Pharmacy Services (promoted 01Aug77 to final rank: Captain, Medical Services Corps)
`
` Supervised 3 outpatient pharmacies and two occupational health clinic pharmacy services
` located in three midwestern states. Served as Secretary of the Pharmacy and Therapeutics
` Committee (drug formulary for Medical/Dental staff). Installed an innovative
` patient profile system that was commended by the JCAH (Joint Commission for Accreditation
` of Hospitals). Replaced rented, gravity-feed capsule/tablet counters with less expensive, vacuum
` based counters. Presented educational seminars to the public on hypertension and
` cardiovascular drug therapy.
`
` U.S. ARMY MEDICAL DEPARTENT – Fort Sam Houston, TX Sept 1975 – Dec 1975
` Pharmacy Officer, Academy of Health Sciences (entry rank: 1st Lieutenant)
` Attended three month orientation/preparation course for Army Pharmacy/Medicine practice
`
` UNIVERSITY of ALABAMA HOSPITALS and CLINICS - Birmingham, AL July 1974 – Sept 1975
`
` Performed parenteral admixture compounding, drug dispensing, and supervised technicians in
` decentralized operation. Selected as first pharmacy intern assigned to rotation in
` surgery/anesthesia department. Completed rotations in inpatient pharmacy (adult/pediatric/
` cardiac/critical care/recovery/acute emergencies), manufacturing/repackaging, stock inventory
` control, and ambulatory pharmacy.
`
`
`
`
`6
`
`

`

`EDUCATION
`
` Ph.D., Pharmaceutical Sciences - University of Mississippi, University, MS Jan 1982 – Aug 1985
` M.S., Pharmaceutics - University of Mississippi, University, MS Aug 1979 – Dec 1981
` B.S., Pharmacy - Auburn University, Auburn, AL
` Sep 1969 -June 1974
`
`
`
` Patents
`
` F. C. Greaves, M. W. Beasley, J. S. Swarbrick, H. C. Caldwell, and A. W. Suddith, " Method for
` Preparing Low Dose Pharmaceutical Product
`• U.S. Patent 5,976,570 (November 2, 1999)
`• South African Patent 93/95565 (September 28, 1994)
`
`
` F.C. Greaves, M.W. Beasley, J.S. Swarbrick, "Method for Dry Blend Compression of
` Medicaments"
`• U.S. Patent 5,928,668 (July 27, 1999)
`• South African Patent 93/9566 (September 28, 1994)
`
`Patent Applications
`
`Lisa Grimes, David Reed, Marty Beasley, Alan Boyd, and Lloyd Frick, “Feedstock for Polyester Yarn and
`Fiber” U.S. Patent Application No. 62/016,634 File date June 24, 2014
`
`
`Lisa Grimes, David Reed, Marty Beasley, Alan Boyd, and Lloyd Frick, “Feedstock for Synthetic Polymer
`Yarn and Fiber” U.S. Patent Application No. 62/043,535 File date August 29, 2014
`
`Martin W. Beasley, David P. Hause, David J. Reynolds, “Pharmaceutical Compositions for the Treatment
`of Pain” U.S. Patent Application No. 12/125,511 and PCT/US2008064625 File date May 23, 2008.
`
`Martin W. Beasley, Kevin H. Sills, Edward P. Leung, “Pharmaceutical Compositions for Promoting
`Wound Healing” U.S. Patent Application Publication US 2007/0232561 A1 Publication date October 4,
`2007; U.S. Patent Application No. 11/729,624 File date March 29, 2007
`
`Martin W. Beasley, David P. Hause, Irwin Klein, Charles L. Pamplin, David J. Reynolds, Kevin.H. Sills,
`“Controlled Release Pharmaceutical Compositions of Liothyronine and Methods of Making and Using
`the Same” U.S. Patent Application No. 11/396,420 and PCT/US2006/12272 File date March 31, 2006
`
`Edward S. Wilson, Martin W. Beasley, “Stabilized Individually Coated Ramipril Particles, Composition
`and Methods” U.S. Patent Application No. 11/269,388; File date November 7, 2005 abandoned
`
`E.S. Wilson, M.W. Beasley, D. P. Hause, K.H. Sills, M.K. Jolly, “Compositions of Stabilized Ramipril in
`Combination with Another Active Agent” U.S. Provisional Application No. 60/736,947; File date
`November 7, 2005 abandoned
`
`
`
`
`
`
`7
`
`

`

`Publications
`
` 5
`
` Excipient monographs: Isopropyl Alcohol, Magnesium. Carbonate, Petrolatum and Lanolin
`Alcohols, Sodium Ascorbate and Starch (Sterilizable Maize), Handbook of
`Pharmaceutical Excipients, 3rd Edition, A.H. Kibbe, ed., American Pharmaceutical
`Association, 1999
`
`Greaves, F.C., Beasley, M.W., Suddith, A.W., and Swarbrick, J., "Novel Approaches to the
`Preparation of Low-Dose Solid Dosage Forms”, Pharm.Tech.,19:60-64, (1995)
`
`Beasley, M.W., Skierkowski, P., Cleary, R.W., Kibbe, A.H., and Jones, A.B., "A
`Comparison of High Pressure Liquid Chromatography and Radioimmunoassay in the
`Determination of Content Uniformity of DigoxinTablets", J.Pharm.Sci., 72:505-508,
`(1983)
`
`Skierkowski, P. and Beasley, M., "Effect of Gamma-Radiation on Yield of Insulin from
`Beef Pancreas Glands", J.Pham.Sci.,63:964-965 (1974)
`
`Abstract
`
`Sinar, D.R., Ellis, P., Beasley, M., Hong, D., and Swarbrick, J., "Gastric irritant potential
`of Pro-Sorb Liquid Sulindac and Clinoril Tablets in the Monkey", Pharm.Res.12 (9)
`Poster S-108 (1995)
`
`Presentations 2004 to present
`
`NC-HOSA Post-Secondary Leadership Conference, North Carolina State University, February 15, 2014,
`“Pharmacy: A Next Level Career Option”
`
`North Carolina Pharmaceutical Discussion Group, 5th Annual Winter Event, December 7, 2012, Durham,
`NC “Formulating a Brick for Potential Treatment of Neuropathic Pain”
`
`King Pharmaceuticals Scientific Operations’ Science Day, September 23, 2008, Cary, NC “T-62 Case
`Study: Utilizing Gamma Scintigraphy to Predict Oral Absorption”, poster
`
`King Pharmaceuticals Research and Development’s Bring Your Kids to Work Day, April 26, 2007, Cary,
`NC “Drug Development Overview”
`
`Pacific Region Clinical Supplies (PARC) Spring Meeting, April 22, 2005, LaJolla, CA “Identifying and
`Managing CMC Contractors: Experience from Both Sides of the Table”
`
`Chinese Association of Science & Technology (CAST), March 12, 2005, RTP, NC “Identifying and
`Managing CMC Contractors: Experience from Both Sides of the Table”
`
`Drug Information Association Workshop, March 2004, Bethesda, MD “Identify and Utilize Contract
`Formulators to Access Drug Delivery Systems: When to Start and How to Achieve Your Objectives”
`
`
`
`
`
`
`8
`
`

`

`
`
`Presentations 1982 - 2001
`
`AAI, Inc., "Controlled Substances Regulations for the Pharmaceutical Industry"
`
`September 2001
`Philadelphia, PA
`July 2000
`Chicago, IL
`December 1999
`San Juan, PR
`July 1999
`San Diego, CA
`May 1999
`New Brunswick, NJ
`September 1998
`Atlanta, GA
`May 1997
`Wilmington, NC
`August 1996
`Morristown, NJ
`May 1996
`Chapel Hill, NC
`
`AAI, Inc., Seminar Series (Internal Training for AAI personnel)
`September 2000
`Veterinary Tablet Formulation Case Study
`July 2000
`Rationale for Classification of Toxic Drugs and Biologicals
`February 2000
`Semi-Solid Formulations & Parenteral Formulations
`August 1999
`Clinical Trial Materials: Work Faster by Being Smarter
`October 1998
`Clinical Trial Materials --- 3 W's for Doing it Right
`
`
`New Hanover County Science Fair, podium presentation "Science Careers in the
`Pharmaceutical Industry"; University of North Carolina-Wilmington, March 2000
`
`American Association of Pharmaceutical Scientists Annual Meeting, Clinical Sciences
`Section, poster presentation "Gastric Irritant Potential of Pro-Sorb Liquid Sulindac and
`Clinoril Tablets in the Monkey", Sinar, D.R., Ellis, P., Beasley, M., Hong, D., and
`Swarbrick, J., Miami, FL, November 1995
`
`Palais Des Congress, Pharmaceutical Technology Conference, poster presentation "Novel
`Approaches to the Preparation of Low Dose Pharmaceutical Products", Greaves, F.C.,
`Beasley, M.W., Suddith, A.W., and Swarbrick, J.; Strasbourg, France, April 1994
`
`Auburn University School of Pharmacy Career Week, invited podium presentation
`"Pharmaceutical Careers in the Pharmaceutical Industry"; Auburn, AL, January 1993
`
`Applied Analytical Industries, Inc., Stability Seminar, podium presentation "A
`Formulator's Perspective of Stability Studies"; Wrightsville Beach, NC, September 1991
`
`American Pharmaceutical Association Annual Meeting, Academy of Pharmaceutical
`Sciences, Basic Pharmaceutics Section, podium presentation "A Dosage Form Design to
`Improve the Bioavailability of Levodopa: Microencapsulation with Serum Albumin",
`San Francisco, CA, March, 1986
`
`American Pharmaceutical Association Annual Meeting, Academy of Pharmaceutical
`Sciences, Analysis and Control Section, podium presentation "A Comparison of HPLC
`and RIA in the Determination of Content Uniformity of Digoxin Tablets"; Las Vegas,
`NV, April, 1982
`
`
`
`
`
`9
`
`

`

`Professional Associations/Activities
`
`Alabama Pharmacy License (current to date)
`
`American Association of Pharmaceutical Scientists (AAPS)
`
` Formulation Design and Development group member
`
` Physical Pharmacy and Biopharmaceutics group member
`
`
`
`
`American Pharmaceutical Association (APhA)
`
`
`
`
`
`Coordination Committee member for the 2nd Southeastern Regional Meeting
`Wrightsville Beach, NC April 1992
`
`Member, Academy of Pharmaceutical Research (APRS) and Science Awards
`Committee, 1989
`
`Member, Editorial Advisory Board American Pharmacy (official APhA
`Journal, 1988-1989
`
`New Hanover Pharmaceutical Association (Wilmington, NC)
`
`
`
`
`Member, North Carolina Pharmaceutical Discussion Group
`
`
`Member, Triangle College of Clinical Pharmacists
`
`
`
`President, 1997-1998
`Vice President, 1996-1997
`
`
`
`
`
`
`
`
`
`10
`
`